Editor’s Perspective
-
547MiSight® 1 Day FDA Approval: Why It Matters
MiSight® 1 day’s FDA approval is an important step forward in stopping the myopia epidemic facing American children.
-
1.9KAn Important New Approach to Managing Progressive Myopia
Results of a recent study on combining orthokeratology and topical atropine 0.01%.
-
3.3KBeware of Snake Oil
When I speak with eye care professionals I am surprised by how much snake oil exists.
-
2.0KThank You, Global Myopia Awareness Coalition
Jobson Optical Research, sponsored by Essilor, polled more than 300 optometrists in the U.S.
-
915‘What Happens If I Do Nothing?’
Myopia was once considered a simple refractive error with few, if any, long-term eye health consequences.
-
484Opportunities Abound for Proactive Myopia Care
By Dwight Akerman, OD, MBA, FAAO Chief Medical Editor, Review of Myopia Management During May 2019, Jobson Optical Research, sponsored by Essilor,...
-
581
Focus On What We Know, Not What We Don’t Know
While we have much to learn about myopia management in children and teenagers, we already know so much.
-
471Proactively Addressing Progressive Myopia
Congratulations to all who created the International Myopia Institute (IMI) Myopia White Papers.
-
588Whom to Target With Myopia Management Intervention?
Thank you for your support for Review of Myopia Management.
-
490Why is Myopia Management Important?
The answer comes from articles written by leaders in myopia care.
